A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

H8H-MC-LAIJ -

The reason for this study is to see how effective and safe the study drug known as lasmiditanis in the acute treatment of 4 migraine attacks with or without aura.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Migraines
What the trial is testing?
Lasmiditan
Could I receive a Placebo?
Yes
Enrollment Goal
1633
Trial Dates
Jun 24, 2019 - Jul 8, 2021
How long will I be in the trial?
The study will last about 20 weeks and may include up to 6 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have migraine with or without aura and willing to complete an eDiary

  • Participant must have history of disabling migraine for at least 1 year, with migraine onset before the age of 50 years

  • Participant must have history of 3 to 8 migraine attacks per month (<15 headache days per month) during the past 3 months

Participants Must Not:

  • Participant must not have history of dizziness

  • Participant must not have increased risk of having seizures

  • Participant must not have diabetes that has caused other serious health problems

  • Participant must not have history, within past 12 months, of chronic migraine or other forms of chronic headache disorder

  • Participant must not have recently started taking a new migraine preventive medication or have started taking a different dose of a preventive migraine medication

  • Participant must not have certain serious infections or medical conditions, including history of drug or alcohol dependence in past year

  • Participant must not be pregnant or breastfeeding

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.